RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Innovent Biologics of Suzhou reported that its PD-1 candidate, sintilimab, produced a 68% objective response rate in first-line patients with non-squamous non-small cell lung cancer. Sintilimab was administered in combination with pemetrexed and cisplatin in the Phase I trial. Based on the data, Innovent said it would start a 378-patient Phase III trial of the drug in the same population. China’s NMPA has already accepted Innovent’s NDA filing for sintilimab under Priority Status rules as a treatment for classical Hodgkin’s Lymphoma.
Source: China Biotoday
